Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis
NCT ID: NCT05681442
Last Updated: 2025-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
600 participants
INTERVENTIONAL
2023-11-13
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Beta-Lactam InfusioN Group Study
NCT03213990
Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic Patients
NCT05024565
Short-course Antimicrobial Therapy in Sepsis
NCT02899143
A STUDY BEFORE/AFTER THE IMPLEMENTATION OF AN ANTI-INFECTIOUS PRESCRIPTION AID
NCT05140213
Evaluation of the Performance of a New Rapid Bacteremia Test in the Intensive Care Patient
NCT06241248
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be randomized to one of four of the following treatment groups in a 1:1:1:1 ratio. Randomization will be stratified on the centre and the initial βL administered (meropenem versus other) to receive (i) βL antibiotic either as a continuous infusion: CID group or as intermittent infusion: IID group, and (ii) either at most 1 dose (short duration) : AMT group or 5 days (long duration) : ACT group of aminoglycoside
* Arm A: continuous infusion dosing of a pivotal βL-AB (Antibiotics) (CID group) AND AG (Aminoglycoside) infusion for 5 days (long duration) as appropriate combination therapy (ACT group)
* Arm B: intermittent infusion dosing of a pivotal βL-AB (IID = control group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT = group)
* Arm C: continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion at most 1 dose (AMT group)
* Arm D: intermittent infusion dosing of a pivotal βL-AB (IID = group) AND AG infusion at most 1 dose (AMT group)
The primary objective of the study is to compare the 30-day mortality of patients with hospital-acquired sepsis in the ICU according to the mode of administration of the pivotal βL antibiotic (CID group vs. IID group).
The primary endpoint is the mortality rate at day 30 between CID and IID groups while the Co-primary objective is to compare the MAKE 30 (Major Adverse Kidney Events within 30 days) between patients that will receive an appropriate monotherapy with βL (AMT group) or an appropriate combination therapy with βL and 5 days of AG (ACT group).
moreover, The co-primary criterion is the percentage of patients with a MAKE 30, i.e. when patients met one of the following criteria within day 30: in-hospital mortality, receipt of renal replacement therapy (RRT) or persistent renal dysfunction (discharge serum creatinine/baseline serum creatinine ≥200%) between AMT and ACT groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
continuous infusion dosing of a pivotal AND AG infusion for 5 days
continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT group)
continuous pivotal βL-AB
continuous pivotal βL-AB
AG infusion for 5 days
AG infusion for 5 days (ACT Group)
intermittent infusion dosing of a pivotal βL-AB ND AG infusion for 5 days
intermittent infusion dosing of a pivotal βL-AB (IID = control group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT = group)
intermittent pivotal βL-AB
intermittent pivotal βL-AB (IID = control group)
AG infusion for 5 days
AG infusion for 5 days (ACT Group)
continuous infusion dosing of a pivotal βL-AB AND AG infusion at most 1 dose
continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion at most 1 dose (AMT group )
continuous pivotal βL-AB
continuous pivotal βL-AB
AG infusion most 1 dose
AG infusion most 1 dose (AMT group )
intermittent infusion dosing of a pivotal βL-AB AND AG infusion at most 1 dose
intermittent infusion dosing of a pivotal βL-AB (IID = group) AND AG infusion at most 1 dose (AMT group)
intermittent pivotal βL-AB
intermittent pivotal βL-AB (IID = control group)
AG infusion most 1 dose
AG infusion most 1 dose (AMT group )
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
continuous pivotal βL-AB
continuous pivotal βL-AB
intermittent pivotal βL-AB
intermittent pivotal βL-AB (IID = control group)
AG infusion most 1 dose
AG infusion most 1 dose (AMT group )
AG infusion for 5 days
AG infusion for 5 days (ACT Group)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospital-acquired sepsis (according to sepsis 3.0 definitions) :
* Patient hospitalized for more than 48 hours OR Patient discharged less than 48 hours ago
* AND sepsis diagnosed within the last 24 hours
* One of the following risk factors for gram negative multidrug resistant pathogens:
* Prior intravenous antibiotic use within 7 days prior to sepsis onset with the exception of antibiotic effective only against Gram-positive bacteria, penicillin A and macrolides
* Prolonged hospital stay (≥ 15 days of hospitalization) within 3 months prior to sepsis onset Prolonged mechanical ventilation (≥ 5 days on mechanical ventilation) within 3 months prior to sepsis onset
* Patients with indwelling devices (dialysis access lines, intravascular lines, urinary catheter, endotracheal or tracheostomy tube, gastrostomy or jejunostomy feeding tube)
* Patients known to be infected, colonized or carriers of MDR gram negative bacteria within 3 months prior to sepsis onset
* Exposure to an antibiotic (amoxicillin-clavulanic acid, C2G, C3G, fluoroquinolones) within 3 months prior to sepsis onset
* A trip abroad to known geographical areas at risk (in particular the Indian subcontinent, South-East Asia, the Middle East and North Africa, the Mediterranean Basin) within 3 months prior to sepsis onset
* A functional or organic abnormality of the urinary tract in case of urinary tract infection.
* Appropriate bacteriological sampling performed before starting antimicrobial therapy
* Expected stay in ICU of more than 3 days
Exclusion Criteria
* Need for extrarenal treatment at inclusion according to the criteria of Gaudry et al.
* Known hypersensitivity to ceftazidime, piperacillin-tazobactam, cefepime, meropenem, ceftazidime-avibactam, ceftazolane-avibactam or to any of the excipients included in the corresponding pharmaceutical drugs,
* Known hypersensitivity to any cephalosporin antibacterial agent,
* Know hypersentitivity to any penem antibacterial agent,
* Severe known hypersensitivity (eg, anaphylactic reaction, severe skin reaction) to any other beta-lactam antibiotic (eg, penicillins or monobactam ) or to any of its excipients.
* Known contraindication to the aminoglycoside family including
* Hypersensitivity to the active substance, to any aminoglycoside antibacterial agent or to any of the excipients included in the corresponding pharmaceutical drugs,
* Cirrhosis of grades B and C according to the Child-Pugh classification.
* Myasthenia gravis.
* Simultaneous administration of another aminoglycoside
* Association with ataluren
* Non-complicated urinary tract infection (corresponding to a positive ECBU not responsible for sepsis)
* Bone marrow transplant or chemotherapy-induced neutropenia
* Infections for which long-term antibiotic treatment \> 8 days is strongly recommended (i.e., infective endocarditis, osteoarticular infections, anterior mediastinitis after cardiac surgery, hepatic or cerebral abscesses, chronic prostatitis for instance
* Presence of antibiotic therapyfor the new sepsis before randomisation: (\> 2 doses of antibiotics or \> 16h for continuous infusion
* Limitation of life support (comfort care applied only) at the time of screening
* Enrolment to another interventional drug study
* Pregnancy or breastfeeding
* Subject deprived of freedom, subject under a legal protective measure
* Non affiliation to any health insurance system
* Refusal to participate to the study (patient or legal representative or family member or close relative if present)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aline DECHANET
Role: STUDY_CHAIR
Assistance Publique - Hôpitaux de Paris (AP-HP)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Médecine intensive - réanimation - CHU Amiens-Picardie
Amiens, , France
Réanimation polyvalente - CH d'Argenteuil - Hôpital Victor Dupuy
Argenteuil, , France
Réanimation polyvalente - CH Avignon
Avignon, , France
Médecine intensive - réanimation - CHU Bordeaux - Hôpital Pellegrin
Bordeaux, , France
Médecine intensive - réanimation - Ambroise Paré
Boulogne-Billancourt, , France
Médecine intensive - réanimation - CHU Gabriel Montpied
Clermont-Ferrand, , France
Anesthésie - Réanimation - Beaujon
Clichy, , France
Réanimation polyvalente/Surveillance continue - CH Sud Essonne-Etampes
Étampes, , France
Médecine intensive - réanimation-Centre Hospitalier Départemental Vendée
La Roche-sur-Yon, , France
Médecine intensive - réanimation - CHU Grenoble-Alpes Hôpital Michallon
La Tronche, , France
Réanimation polyvalente - CH de Versailles - Hôpital André Mignot
Le Chesnay, , France
Réanimation Médico Chirurgicale & USC - CH Le Mans
Le Mans, , France
Médecine Intensive Réanimation - Hôpital Croix Rousse
Lyon, , France
Médecine intensive - réanimation - HCL - Edouard Herriot
Lyon, , France
Réanimation polyvalente - CHR Metz-Thionville - Hôpital de Mercy
Metz, , France
Médecine intensive - réanimation - CHU Montpellier - Hôpital Lapeyronie
Montpellier, , France
Réanimation Chirurgicale - Saint Eloi
Montpellier, , France
Médecine Intensive Réanimation - Pasteur 2
Nice, , France
Médecine intensive - réanimation - CHU Nice - Hôpital Archet
Nice, , France
Médecine intensive - réanimation
Orléans, , France
Anesthésie - Réanimation - CHU Orléans
Orléans, , France
Médecine intensive et réanimation infectieuse - Bichat
Paris, , France
Réanimation chirurgicale - Bichat
Paris, , France
Institut Mutualiste du Montsouris
Paris, , France
Médecine intensive - réanimation - CHU Poitiers - Site de la Milétrie
Poitiers, , France
Médecine intensive et réanimation polyvalente 6 CHU de Reims - Hôpital Robert Debré
Reims, , France
Médecine intensive - réanimation-CH St Denis - Hôpital Delafontaine
Saint-Denis, , France
Médecine intensive - réanimation - CHU de Strasbourg - Nouvel Hôpital Civil
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP180596
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.